Perioperative urinary excretion of aquaporin-2 dependent upon vasopressin in cardiac surgery
Aquaporin-2 is found in the apical cell membranes of the principal cells of the collecting duct of the kidney. Plasma arginine vasopressin has been reported to be markedly elevated during cardiac surgery. However fluctuations in urine aquaporin-2 levels have never been reported. We aimed to determine the responses of urine aquaporin-2 and evaluated the relationship between urine aquaporin-2 and plasma arginine vasopressin levels during perioperative periods in cardiac surgical patients. Eight patients undergoing elective isolated aortic valve replacement in normothermia were enrolled prospectively. Blood and urine samples were collected preoperatively and on postoperative days 1, 4, and 7. Patients received furosemide and spironolactone, as needed, during the clinical course; tolvaptan was not needed. Median plasma arginine vasopressin levels [with interquartile range] significantly increased to 1.5 [1.3–2.0], 15.3 [11.4–22.2]*, 2.2 [2.1–2.3], 1.7 [1.5–1.9] pg/mL preoperatively, on postoperative days 1, 4, and 7, respectively (*: p = 0.0001). Similarly, levels of urine aquaporin-2 markedly increased in 3.4 [1.9–5.6], 25.8 [18.4–33.5]**, 9.3 [5.9–14.0], 5.4 [5.3–6.1] (ng/mL), respectively (**p = 0.0004). A significant correlation between plasma arginine vasopressin and urine aquaporin-2 was observed during the entire investigation (R2 = 0.616, p < 0.0001). Plasma arginine vasopressin and urine aquaporin-2 levels were significantly elevated on postoperative day 1 in patients who underwent aortic valve replacement with cardiopulmonary bypass. A significant correlation between plasma arginine vasopressin and urine aquaporin-2 was observed. Urine aquaporin-2 should be further investigated as a potential biomarker for postoperative cardiac dysfunction.
KeywordsAquaporin 2 Arginine vasopressin Brain natriuretic peptide Cardiopulmonary bypass
The authors thank Dr. Kazutora Mizukami, president of Medical Data Management, Fukuoka, for the assistance in the statistical analysis. We would also like to thank Editage (www.editage.com) for English language editing.
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by MF and RA. Funding acquisition was performed by RA. Writing—review and supervision—were performed by RB. The first draft of the manuscript was written by MF and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
This work was supported by JSPS KAKENHI Grant No. JP16K10642.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 17.Philbin DM, Levine FH, Emerson CW, Coggins CH, Buckley MJ, Austen WG (1979) Plasma vasopressin levels and urinary flow during cardiopulmonary bypass in patients with valvular heart disease: effect of pulsatile flow. J Thorac Cadiovasc Surg 78:779–783Google Scholar
- 19.Nielsen S, Terris J, Andersen D, Ecelbarger C, Frokiaer J, Jonassen T, Marples D, Knepper MA, Petersen JS (1997) Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci USA 94:5450–5455CrossRefGoogle Scholar
- 20.Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA 297:1319–1331CrossRefGoogle Scholar
- 21.Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M (2008) Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 52:1540–1545CrossRefGoogle Scholar
- 23.Matsuzaki M, Hori M, Izumi T, Fukunami M (2011) Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study QUEST study. Cardiovasc Drugs Ther 25(Suppl 1):S33–S45CrossRefGoogle Scholar
- 25.Takagi K, Sato N, Ishihara S, Sone M, Tokuyama H, Nakama K, Omote T, Kikuchi A, Ishikawa M, Amitani K, Takahashi N, Maruyama Y, Imura H, Shimizu W (2018) Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria. Heart Vessels 33:413–420CrossRefGoogle Scholar
- 26.Nishi H, Toda K, Miyagawa S, Yoshikawa Y, Fukushima S, Kawamura M, Yoshioka D, Saito T, Ueno T, Kuratani T, Sawa Y (2015) Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial. Surg Today 45:1542–1551CrossRefGoogle Scholar